Top Biotech /Drug companies   performances and pricing, investment strategy
(Two master hands controlling Biotech    stock prices

This column recommended buy biotech   IPO  and biotech stocks after 50 % correction strategy made up to 500 % gain for  Celera ( drop from 250 to 130 nback to 200 and split, recnet plunge from 150 to 55 in May, and rebound to 140) DNA down ftom 200 to 100 and recent plunge to 100 and rebound to 150 , IMNX plunge from 78 to 25 in May , Dr Huang recommended bto buy as Nasdaq around 3000, it more than doubled to 56 in recent Nasdaq rally from 3000 to 4050, Pfzer, SGP  plunge from 58 to 30 , rebound from 30 to 48..... endless lists

All stocks, the Blue chips IPO, the hitechs and internet , biotech IPO stock prices are determined by supply, demand, and investors sentiment, to put more specifically, are related to central banks monetary policy impact on the economy and the financial markets.

Dr. Warren Huang have developed thousands of these relationship for tracking last 20 years global economy, stocks prices with average error below 1.5 %, It predicted the Dow crash in 1987, last Sept. LTCM recent new high of 11300 and this week retreat to 10000,  Bubble appear again as Dr. Huang accurate prediction buy biotech, IT share as Nasdaq around 3000 in May, these stocks more than doubled . Bubble will burst, stock prices compression again as more earning decline warning lead to markets plunge to new low before Aug:
IPO and internet bubble burst in Apr 2000, after Greenspan 5 interest rate hikes to cooloff overheated stocks, housing markets resulted wealth effect, excessive consumer, business demand. Nasdaq plunge 35 % to 3200, Dow plunge 700 single day, most  IPO internet , BIOTECHstocks soared 1000 %, plunged below 75 % to 90 %  AND BELOW THEIR ipo PRICES

For Internet stock index are related to US Fed money supply growth, interest rate and investor sentiment (Nasdaq index), as for individua BIOTECH.. IPO stock prices, they are related to the  stock and Nasdaq index (investor sentiment in internet) and corporate revenue and earning outlook(depend on  NEW DRUG DEVELOPEMENT, COMMERCIALIZATION, PROFIT, MARGIN, MARKET SHARES ex Biotec sahre were estremely volatile and overpriced by the publicity of completion og Genome, mostly from CELERA, We acurately precited last Dec  and early this yearon sina.como and this website that all these bubble will burst: down 30 -50 %  correction earlier this year:

Biotech drug investment strategy:

 The biotech genome star Celera plunge from 250 to 51 as Nasdaq plunge to 3000 in May ,  accurately predicted by Dr Huang recommed to buy biotech shares, it rebound to 140 , These bubble appeared again in biotech and drugs  will burst again as Nasdaq plunge to 3000, will be another buy opportunites

Biotech IPO Performances, investment strategy

These stocks are still under corrections in the weeks ahead: all stocks with poor earning outlook will be dropped to below 100 (DNA) deflated and compressed to 40- 65 (CRA) range. Those with widening loss will be down to below 30. Then will will see  buying opportunties in summer after the markets and economy cooled off

Over 30 million China, Taiwan government, banking, finance, corporate CEO, fund managers, analyst, traders, investors have been benefited by my analysis on China's 12 cities , Taiwan TV, radio daily, weekly commentary , and workshops since 1987